- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
PURPOSE: Osteoporosis is a severe health problem with social and economic impacts on society. The standard treatment consists of the systemic administration of drugs such as bisphosphonates, with alendronate (ALN) being one of the most common. Nevertheless, complications of systemic administration occur with this drug. Therefore, it is necessary to develop new strategies, such as local administration. METHODS: In this study, emulsion/dispersion scaffolds based on W/O emulsion of PCL and PF68 with ALN, containing hydroxyapatite (HA) nanoparticles as the dispersion phase were prepared using electrospinning. Scaffolds with different release kinetics were tested in vitro on the co-cultures of osteoblasts and osteoclast-like cells, isolated from adult osteoporotic and control rats. Cell viability, proliferation, ALP, TRAP and CA II activity were examined. A scaffold with a gradual release of ALN was tested in vivo in the bone defects of osteoporotic and control rats. RESULTS: The release kinetics were dependent on the scaffold composition and the used system of the poloxamers. The ALN was released from the scaffolds for more than 22 days. The behavior of cells cultured in vitro on scaffolds with different release kinetics was comparable. The difference was evident between cell co-cultures isolated from osteoporotic and control animals. The PCL/HA scaffold show slow degradation in vivo and residual scaffold limited new bone formation inside the defects. Nevertheless, the released ALN supported bone formation in the areas surrounding the residual scaffold. Interestingly, a positive effect of systemic administration of ALN was not proved. CONCLUSION: The prepared scaffolds enabled tunable control release of ALN. The effect of ALN was proved in vitro and in in vivo study supported peri-implant bone formation.
- MeSH
- alendronát * farmakologie MeSH
- emulze farmakologie MeSH
- hydroxyapatit farmakologie MeSH
- inhibitory kostní resorpce * farmakologie MeSH
- krysa rodu rattus MeSH
- osteoblasty MeSH
- osteogeneze MeSH
- osteoklasty MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Publikační typ
- abstrakt z konference MeSH
Midazolam is a short acting sedative with small number of adverse effects. Administered orally, it is currently the most common form of conscious sedation in children. The objective of this paper is to describe effect of midazolam administered to children during dental treatment on their vital signs, and to monitor changes in children's behavior. We described values of vital signs and behavior in 418 sedations conducted in 272 children between 1-12 years of age. To achieve the following results, we used data from 272 all first-time sedations. After administration of midazolam arterial blood pressure and blood oxygen saturation decreased by values which were not clinically significant. The heart rate increased, with values staying within the limits of physiological range. The speed of onset of midazolam's clinical effects depends on age and dose. The lower age and dose correlated with the higher behavior score. The effectiveness of midazolam treatment is 97.8 %. Unwillingness of child to receive midazolam is predictor for disruptive behavior during sedation. 1.8 % of all sedation cases showed paradoxical reactions. The administration of midazolam in dose of 0.5 mg per 1 kg of child's body weight is safe and could be recommended for dental treatment in pediatric dentistry.
- MeSH
- analgosedace metody MeSH
- aplikace orální MeSH
- chování dětí účinky léků MeSH
- dítě MeSH
- hypnotika a sedativa aplikace a dávkování MeSH
- kojenec MeSH
- lidé MeSH
- midazolam aplikace a dávkování MeSH
- předškolní dítě MeSH
- vitální znaky účinky léků MeSH
- zubní lékařství metody MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Klíčová slova
- Tamiflu,
- MeSH
- antivirové látky aplikace a dávkování MeSH
- chřipka lidská * diagnóza komplikace terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- umělé dýchání metody MeSH
- virus chřipky B izolace a purifikace patogenita MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- Publikační typ
- abstrakt z konference MeSH
- Klíčová slova
- hexavakcína, odložené očkování kvůli respirační infekci, konjugované pneumokokové vakcíny,
- MeSH
- anamnéza MeSH
- antibakteriální látky * aplikace a dávkování farmakologie terapeutické užití MeSH
- apatie MeSH
- C-reaktivní protein normy MeSH
- edém mozku MeSH
- fatální výsledek * MeSH
- fibrilace komor MeSH
- hemiplegie * diagnóza MeSH
- horečka MeSH
- hospitalizace * MeSH
- infekce dýchací soustavy MeSH
- jednotky intenzivní péče pediatrické * MeSH
- kojenec * MeSH
- laboratoře MeSH
- lidé MeSH
- meningitida * diagnóza etiologie farmakoterapie terapie MeSH
- mozkomíšní mok * mikrobiologie MeSH
- paracetamol aplikace a dávkování farmakologie terapeutické užití MeSH
- péče o pacienty v kritickém stavu MeSH
- pediatrie * metody organizace a řízení pracovní síly MeSH
- pneumokokové vakcíny klasifikace MeSH
- poruchy vědomí MeSH
- resuscitace MeSH
- sepse MeSH
- sérotypizace klasifikace MeSH
- srdeční zástava MeSH
- status epilepticus diagnóza MeSH
- Streptococcus pneumoniae * MeSH
- vakcinace * využití zákonodárství a právo MeSH
- zvracení MeSH
- Check Tag
- kojenec * MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
